respond registry

A Prospective, MultiCenter, large, REAL-WORLD EFFECTIVENESS STUDY FOR PURAPLY® AM

The Real-World Effectiveness Study of PuraPly® AM on Wounds (RESPOND) was the first prospective, large (N=307), multicenter (28 sites) cohort study to assess the effectiveness of PuraPly® AM in various difficult-to-heal wounds.

In a primarily elderly population with large, deep, refractory wounds of long durations, use of PuraPly® AM as an antimicrobial barrier resulted in 86% of all wounds demonstrated improvement in the wound bed condition. Additionally, 41.5% of wounds achieved complete closure at 12 weeks.¹

Study Background

PURAPLY® AM supported healing
in Challenging wounds

The largest real-world effectiveness study demonstrating that
PuraPly® AM supports healing and granulation tissue formation¹

the study

THE RESULTS

N=307
28 Sites

Prospective, multicenter
cohort study¹

Large
Difficult-to-Heal
Wounds

12.9 cm² mean wound area¹

86%

of wounds demonstrated improvement
in wound bed conditions¹

Increased granulation tissue

Reduced exudate

Readiness for other advanced skin substitutes

85%

of wounds achieved > 75% reduction
in volume¹

REDUCTION IN WOUND AREA, DEPTH, AND VOLUME

81%

of wounds achieved
> 60% reduction in area^1,*

Mean 12.9 cm²
at baseline

71%

of wounds achieved
> 60% reduction in depth^1,*

Mean 5.2 mm
at baseline

85%

of wounds achieved
> 60% reduction in volume^1,*

Mean 11.2 cm³
at baseline

*At 32 weeks

RATES OF WOUND CLOSURE

41.5%

of wounds achieved complete closure at 12 weeks¹

Frequency of wound closure;
all wounds (N=307)

17weeks

Median time to closure
for all wounds¹

Median time to wound closure
by wound type

SUPPORTING HEALING
IN STALLED WOUNDS

See how PuraPly® AM supported healing in chronic wounds that failed ~2 years of prior therapies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly® AM can help your patients.

Please refer to the PuraPly AM Instructions for Use and
PuraPly XT Instructions for Use for complete prescribing information.

References:

1. Bain MA, et al. J Comp Eff Res. 2020;9(10):691-703.